- ►jjeger.ch [PDF] RS Bresalier, RS Sandler, H Quan, JA … - The New England journal of medicine, 2005 - nejm.highwire.org Background Selective inhibition of cyclooxygenase-2 (COX-2) may be associated
with an increased risk of thrombotic events, but only limited long-term data
have been available for analysis. We report on the cardiovascular outcomes ... Cited by 1106 - Related articles - BL Direct - All 25 versions
- ►mt.gov [PDF] DJ Graham, D Campen, R Hui, M Spence, C … - The Lancet, 2005 - Elsevier We used data from Kaiser Permanente in California to assemble a cohort of all
patients age 18–84 years treated with a NSAID between Jan 1, 1999, and Dec 31,
2001, within which we did a nested case-control study. Cases of serious ... Cited by 540 - Related articles - All 33 versions
- ►ucr.ac.cr [PDF] P McGettigan, D Henry - Jama, 2006 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... JAMA. 2006;296:1633-1644. ... Cited by 372 - Related articles - BL Direct - All 9 versions
- ►nih.gov T Grosser, S Fries, GA FitzGerald - Journal of Clinical Investigation, 2006 - Am Soc Clin Investig Inhibitors selective for prostaglandin G/H synthase-2 (PGHS-2) (known
colloquially as COX-2) were designed to minimize gastrointestinal complications
of traditional NSAIDs — adverse effects attributed to suppression of ... Cited by 329 - Related articles - BL Direct - All 10 versions
- ►annals.org LE Levesque, JM Brophy, B Zhang - Annals of internal medicine, 2005 - Am Coll Physicians Background: Cyclooxygenase-2 (COX-2) selective inhibitors have been marketed
since 1999 as safer alternatives to nonsteroidal anti-inflammatory drugs
(NSAIDs). Debate about their cardiac safety has culminated in the recent ... Cited by 195 - Related articles - All 15 versions
SP Johnsen, H Larsson, RE Tarone, JK … - Archives of Internal Medicine, 2005 - archinte.highwire.org Methods Using data from hospital discharge registries in the counties of North
Jutland, Viborg, and Aarhus, Denmark, and the Danish Civil Registration System,
we identified 10 280 cases of first-time hospitalization for MI and 102 797 ... Cited by 194 - Related articles - All 7 versions
- ►ahajournals.org GH Gislason, S Jacobsen, JN Rasmussen, S … - Circulation, 2006 - Am Heart Assoc Methods and Results— All patients with first-time MI between 1995 and 2002 as
well as all prescription claims for NSAIDs after discharge were identified from
nationwide Danish administrative registers. The risk of death and ... Cited by 145 - Related articles - All 7 versions
- ►pfizerpro.com [PDF] G Singh, JG Fort, JL Goldstein, RA Levy, PS … - The American journal of medicine, 2006 - Elsevier Results from all primary efficacy assessments showed that both dosages of
celecoxib were as effective as NSAIDs in treating osteoarthritis. Significantly
more ulcer complications occurred within the nonselective NSAID group ... Cited by 127 - Related articles - All 16 versions
- ►direct-ms.org [PDF] EJ Topol - Jama, 2005 - Am Med Assoc A significant excess of major cardiovascular events was demonstrated, with a
dose-response effect (odds ratio, 2.5 for celecoxib 400-mg dose, and 3.4 at the
800-mg dose, vs placebo) (Figure). The absolute excess of major ... Cited by 114 - Related articles - All 8 versions
EM Antman, D DeMets, J Loscalzo - Circulation, 2005 - Am Heart Assoc Over the past several months clinicians have been confronted at an escalating
rate with reports describing the risks of COX-2 inhibitors (coxibs). Information
on this class of drugs appears not only in traditional medical journals and ... Cited by 111 - Related articles - All 7 versions
